Scientific Papers

Cross-walk of the Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) and the EuroQol EQ-5D-5L in patients with NASH | Health and Quality of Life Outcomes


  • Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411–28.

    Article 
    PubMed 

    Google Scholar
     

  • Dufour J-F, Scherer R, Balp M-M, McKenna SJ, Janssens N, Lopez P, et al. The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors–A targeted literature review. Endocr Metab Sci. 2021;3:100089.

    Article 
    CAS 

    Google Scholar
     

  • Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hamid O, Eltelbany A, Mohammed A, Alsabbagh Alchirazi K, Trakroo S, Asaad I. The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010–2020: a population-based study. Ann Hepatol. 2022;27(5):100727.

    Article 
    PubMed 

    Google Scholar
     

  • Witkowski M, Moreno SI, Fernandes J, Johansen P, Augusto M, Nair S. The economic burden of non-alcoholic steatohepatitis: a systematic review. Pharmacoeconomics. 2022;40(8):751–76.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Dufour J-F, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, et al. Current therapies and new developments in NASH. Gut. 2022;71(10):2123–34.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Younossi Z, Aggarwal P, Shrestha I, Fernandes J, Johansen P, Augusto M, et al. The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes. JHEP Rep. 2022;4(9):100525.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Younossi ZM, Stepanova M, Younossi I, Racila A. Validation of chronic liver disease questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(10):2093-2100.e2093.

    Article 
    PubMed 

    Google Scholar
     

  • Longworth L, Yang Y, Young T, Mulhern B, Hernández Alava M, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1–224.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.

    Article 

    Google Scholar
     

  • Position statement on use of the EQ-5D-5L value set for England (updated October 2019). Available from:
    https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l.

  • ICER’s reference case for economic evaluations: Principles and rationale. Available from:
    https://icer.org/wp-content/uploads/2020/10/ICER_Reference_Case_013120.pdf.

  • Longworth L, Rowen D. NICE decision support unit technical support documents. In: NICE DSU technical support document 10: the use of mapping methods to estimate health state utility values. London: National Institute for Health and Care Excellence (NICE); 2011.


    Google Scholar
     

  • Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.

    Article 
    PubMed 

    Google Scholar
     

  • Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Health. 2017;20(1):18–27.

    Article 
    PubMed 

    Google Scholar
     

  • Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, et al. Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis. Clin Gastroenterol Hepatol. 2022;20(9):2050-2058.e2012.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Younossi ZM, Stepanova M, Noureddin M, Kowdley KV, Strasser SI, Kohli A, et al. Improvements of fibrosis and disease activity are associated with improvement of patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis. Hepatol Commun. 2021;5(7):1201–11.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes – a means to understand. Curr Med Res Opin. 2008;24(11):3063–72.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–80.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, et al. United States valuation of EQ-5D-5L Health States using an international protocol. Value Health. 2019;22(8):931–41.

    Article 
    PubMed 

    Google Scholar
     

  • EQ-5D-5L User Guide. Version 3.0. Available from:
    https://euroqol.org/publications/user-guides.

  • Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration. Pharmacoeconomics. 2015;33(10):993–1011.

    Article 
    PubMed 

    Google Scholar
     

  • Pike J, Dong Y, Piercy J, Booth N, Holdsworth E, Hunter T. Cross-walk of the assessment of spondyloarthritis international society health index and ankylosing spondylitis quality of life scores in ankylosing spondylitis and non-radiographic axial spondyloarthritis patients. Rheumatol Ther. 2021;8(2):849–62.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • McClure NS, Sayah FA, Ohinmaa A, Johnson JA. Minimally important difference of the EQ-5D-5L Index Score in adults with type 2 diabetes. Value Health. 2018;21(9):1090–7.

    Article 
    PubMed 

    Google Scholar
     

  • Harrell F. Regression modeling strategies: With applications to linear models, logistic regression, and survival analysis. New York: Springer International Publishing; 2015.

  • Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.

    Article 
    PubMed 

    Google Scholar
     

  • Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400(10365):1803–20.

    Article 
    PubMed 

    Google Scholar
     

  • GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet. 2023;402(10397):203–34. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01301-6/fulltext.

  • Hu G, Ding J, Ryan DH. Trends in obesity prevalence and cardiometabolic risk factor control in US adults with diabetes, 1999–2020. Obesity (Silver Spring). 2023;31(3):841–51.

    Article 
    PubMed 

    Google Scholar
     

  • Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999–2006. Obes Surg. 2011;21(3):351–5.

    Article 
    PubMed 

    Google Scholar
     

  • StataCorp. Stata Statistical Software: Release 17. College Station: StataCorp LLC.; 2021.


    Google Scholar
     

  • Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803–16.

    Article 
    PubMed 

    Google Scholar
     

  • Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. Int J Technol Assess Health Care. 1995;11(4):796–7.


    Google Scholar
     

  • Canada’s Drug and Health Technology Agency. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.


    Google Scholar
     

  • Guide to the methods of technology appraisal 2013. Available from:
    https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.

  • Agborsangaya CB, Lahtinen M, Cooke T, Johnson JA. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health Qual Life Outcomes. 2014;12(1):74.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yang F, Wong CKH, Luo N, Piercy J, Moon R, Jackson J. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis. Eur J Health Econ. 2019;20(8):1195–206.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kay S, Tolley K, Colayco D, Khalaf K, Anderson P, Globe D. Mapping EQ-5D utility scores from the Incontinence Quality of Life Questionnaire among patients with neurogenic and idiopathic overactive bladder. Value Health. 2013;16(2):394–402.

    Article 
    PubMed 

    Google Scholar
     

  • Iglay K, Hannachi H, Joseph Howie P, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32(7):1243–52.

    Article 
    PubMed 

    Google Scholar
     

  • Kevin MP, Todd MH, Kevin MC, Sheldon XK, Brian JW, Michael WK, et al. Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system. BMJ Open. 2017;7(11):e017583.

    Article 

    Google Scholar
     

  • Boye KS, Ford JH, Thieu VT, Lage MJ, Terrell KA. The association between obesity and the 5-year prevalence of morbidity and mortality among adults with type 2 diabetes. Diabetes Ther. 2023;14(4):709–21.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, et al. Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(12):2552-2560.e2510.

    Article 
    PubMed 

    Google Scholar
     

  • O’Hara J, Finnegan A, Dhillon H, Ruiz-Casas L, Pedra G, Franks B, et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study. JHEP Rep. 2020;2(5):100142.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol. 2019;17(10):2085-2092.e2081.

    Article 
    PubMed 

    Google Scholar
     

  • David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49(6):1904–12.

    Article 
    PubMed 

    Google Scholar
     

  • Balp M-M, Krieger N, Przybysz R, Way N, Cai J, Zappe D, et al. The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: a real-world patient-reported outcomes study. JHEP Reports. 2019;1(3):154–61.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Roudijk B, Janssen B, Olsen JA. How do EQ-5D-5L value sets differ? In: Devlin N, Roudijk B, Ludwig K, editors. Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide. Cham: Springer International Publishing; 2022. p. 235–58.

    Chapter 

    Google Scholar
     

  • Dakin H, Abel L, Burns R, Yang Y. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement. Health Qual Life Outcomes. 2018;16(1):31.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • EphMRA Code of Conduct. 2019. Available from:
    https://www.ephmra.org/media/2811/ephmra-2019-code-of-conduct-doc-f.pdf.

  • Summary of the HIPAA security rule. Available from:
    https://www.hhs.gov/hipaa/for-professionals/security/laws-regulations/index.html.

  • HITECH Act Enforcement Interim Final Rule. Available from:
    https://www.hhs.gov/hipaa/for-professionals/special-topics/hitech-act-enforcement-interim-final-rule/index.html.



  • Source link